| scholarly article | Q13442814 |
| P2093 | author name string | Raktim Kumar Ghosh | |
| Narinder Pal Singh | |||
| Alpana Saxena | |||
| Nitin Kaushik | |||
| Shalini Chawla | |||
| P2860 | cites work | Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 | Q27860575 |
| Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group | Q31976463 | ||
| Efficacy and tolerability of sitagliptin in type 2 diabetic patients inadequately controlled with metformin. A prospective observational study in austrian primary care | Q33858415 | ||
| Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. | Q33864120 | ||
| Review of sitagliptin phosphate: a novel treatment for type 2 diabetes | Q36854023 | ||
| Ethnic differences in body composition and the associated metabolic profile: a comparative study between Asians and Caucasians | Q37676429 | ||
| Incretin therapies in the management of elderly patients with type 2 diabetes mellitus | Q37858364 | ||
| Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. | Q37910902 | ||
| Epidemiology of type 2 diabetes: Indian scenario | Q39796919 | ||
| Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy | Q40099238 | ||
| Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes | Q41976344 | ||
| Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. | Q43294072 | ||
| Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study | Q45074002 | ||
| Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes | Q46804059 | ||
| Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study | Q46885175 | ||
| The rosiglitazone controversy: the Indian perspective. | Q46973224 | ||
| PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. | Q51375536 | ||
| The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. | Q51376983 | ||
| Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. | Q51381989 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. | Q51468797 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. | Q51478110 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. | Q51484788 | ||
| Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. | Q51496275 | ||
| Pioglitazone/metformin | Q79238106 | ||
| Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes | Q94681234 | ||
| P433 | issue | 1 | |
| P921 | main subject | metformin | Q19484 |
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 27-32 | |
| P577 | publication date | 2013-01-01 | |
| P1433 | published in | Journal of Pharmacology & Pharmacotherapeutics | Q15816637 |
| P1476 | title | Effect of addition of either sitagliptin or pioglitazone in patients with uncontrolled type 2 diabetes mellitus on metformin: A randomized controlled trial | |
| P478 | volume | 4 |
| Q49193708 | Comparative Study on Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin |
| Q35964678 | Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins |
| Q28546797 | Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis |
| Q90143955 | Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and β-Cell Function in Type 2 Diabetes Mellitus: A Propensity Score-Matched Analysis |
| Q46624867 | Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis. |
| Q34637776 | Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study |
| Q50168195 | Network meta-analysis of lorcaserin and oral hypoglycaemics for patients with type 2 diabetes mellitus and obesity |
| Q33568852 | Pioglitazone utilization, efficacy & safety in Indian type 2 diabetic patients: A systematic review & comparison with European Medicines Agency Assessment Report |
| Q36105361 | Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). |
| Q47144226 | Sitagliptin 100 mg vs glimepiride 1-3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM). |
| Q64269258 | The Drug Candidate BGP-15 Delays the Onset of Diastolic Dysfunction in the Goto-Kakizaki Rat Model of Diabetic Cardiomyopathy |
| Q35528786 | The effect of pioglitazone on weight, lipid profile and liver enzymes in type 2 diabetic patients |
Search more.